MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program

Zijun Y. Xu-Monette, Michael B. Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu, Ganiraju C. Manyam, Louise Kristensen, Lei Fan, Carlo Visco, Karen Dybkær, April Chiu, Wayne Tam, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, J. Han Van Krieken, Qin Huang, Jooryung HuhWeiyun Ai, Maurilio Ponzoni, Andrés J.M. Ferreri, Lin Wu, Xiaoying Zhao, Carlos E. Bueso-Ramos, Sa A. Wang, Ronald S. Go, Yong Li, Jane N. Winter, Miguel A. Piris, L. Jeffrey Medeiros, Ken H. Young

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences